Technical Analysis for MRUS - Merus N.V.

Grade Last Price % Change Price Change
grade C 12.84 -0.39% -0.05
MRUS closed down 0.39 percent on Friday, March 22, 2019, on 14 percent of normal volume. It was able to find support at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical MRUS trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Support Bullish 0.00%
Mar 22 50 DMA Support Bullish 0.00%
Mar 22 Hammer Candlestick Bullish 0.00%
Mar 22 Lizard Bullish Bullish Day Trade Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Doji - Bullish? Reversal 0.00%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.39%
Mar 21 Narrow Range Bar Range Contraction -0.39%
Mar 20 Crossed Above 20 DMA Bullish -0.08%
Mar 20 Crossed Above 50 DMA Bullish -0.08%

Older signals for MRUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Medicine Health Immunology Solid Tumors Antibodies Monoclonal Antibodies Cancer Immunotherapy Acute Myeloid Leukemia Myelodysplastic Syndrome Monoclonal Antibody Therapy Europe Ovarian Cancers
Is MRUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.74
52 Week Low 11.0
Average Volume 29,079
200-Day Moving Average 16.6878
50-Day Moving Average 12.5371
20-Day Moving Average 12.8063
10-Day Moving Average 13.0215
Average True Range 0.6085
ADX 14.89
+DI 17.6647
-DI 24.355
Chandelier Exit (Long, 3 ATRs ) 12.0045
Chandelier Exit (Short, 3 ATRs ) 12.8255
Upper Bollinger Band 14.3702
Lower Bollinger Band 11.2424
Percent B (%b) 0.51
BandWidth 24.423916
MACD Line 0.1506
MACD Signal Line 0.1912
MACD Histogram -0.0407
Fundamentals Value
Market Cap 249.05 Million
Num Shares 19.4 Million
EPS -5.48
Price-to-Earnings (P/E) Ratio -2.34
Price-to-Sales 36.17
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.41
Resistance 3 (R3) 13.35 13.10 13.32
Resistance 2 (R2) 13.10 12.96 13.13 13.29
Resistance 1 (R1) 12.97 12.87 12.85 13.03 13.26
Pivot Point 12.72 12.72 12.66 12.75 12.72
Support 1 (S1) 12.59 12.57 12.46 12.65 12.42
Support 2 (S2) 12.34 12.48 12.37 12.39
Support 3 (S3) 12.20 12.34 12.36
Support 4 (S4) 12.27